Stonebridge Financial Group LLC Acquires New Position in Becton, Dickinson and Company (NYSE:BDX)

Stonebridge Financial Group LLC bought a new position in shares of Becton, Dickinson and Company (NYSE:BDX) in the fourth quarter, Holdings Channel reports. The firm bought 15,616 shares of the medical instruments supplier’s stock, valued at approximately $3,543,000.

Other large investors also recently made changes to their positions in the company. Livelsberger Financial Advisory bought a new stake in Becton, Dickinson and Company in the third quarter valued at about $26,000. Ashton Thomas Securities LLC bought a new stake in shares of Becton, Dickinson and Company in the 3rd quarter valued at about $33,000. Tompkins Financial Corp raised its position in shares of Becton, Dickinson and Company by 44.2% in the 3rd quarter. Tompkins Financial Corp now owns 150 shares of the medical instruments supplier’s stock valued at $36,000 after acquiring an additional 46 shares during the period. Sound Income Strategies LLC boosted its stake in Becton, Dickinson and Company by 35.8% during the 3rd quarter. Sound Income Strategies LLC now owns 167 shares of the medical instruments supplier’s stock worth $40,000 after acquiring an additional 44 shares during the last quarter. Finally, Kennebec Savings Bank acquired a new position in Becton, Dickinson and Company during the third quarter valued at approximately $46,000. Institutional investors and hedge funds own 86.97% of the company’s stock.

Insider Transactions at Becton, Dickinson and Company

In related news, Director Jeffrey William Henderson acquired 1,500 shares of the company’s stock in a transaction dated Monday, February 10th. The shares were bought at an average price of $233.62 per share, for a total transaction of $350,430.00. Following the purchase, the director now directly owns 8,015 shares in the company, valued at approximately $1,872,464.30. This trade represents a 23.02 % increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Roland Goette sold 638 shares of the firm’s stock in a transaction on Monday, December 9th. The shares were sold at an average price of $219.03, for a total transaction of $139,741.14. Following the completion of the transaction, the executive vice president now directly owns 14,217 shares of the company’s stock, valued at $3,113,949.51. This represents a 4.29 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 9,844 shares of company stock worth $2,210,716 in the last three months. Insiders own 0.36% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have recently weighed in on BDX. StockNews.com cut shares of Becton, Dickinson and Company from a “buy” rating to a “hold” rating in a research report on Wednesday, December 18th. Piper Sandler lifted their target price on Becton, Dickinson and Company from $275.00 to $280.00 and gave the stock an “overweight” rating in a report on Tuesday, January 28th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the company. According to MarketBeat, Becton, Dickinson and Company presently has an average rating of “Moderate Buy” and an average price target of $283.00.

Becton, Dickinson and Company Stock Down 0.2 %

BDX stock opened at $229.35 on Tuesday. The company has a debt-to-equity ratio of 0.69, a current ratio of 1.13 and a quick ratio of 0.74. The stock has a market capitalization of $66.51 billion, a P/E ratio of 38.10, a P/E/G ratio of 1.65 and a beta of 0.40. Becton, Dickinson and Company has a fifty-two week low of $218.75 and a fifty-two week high of $251.99. The business has a 50-day moving average of $232.07 and a 200-day moving average of $234.02.

Becton, Dickinson and Company (NYSE:BDX) last issued its quarterly earnings results on Wednesday, February 5th. The medical instruments supplier reported $3.43 earnings per share for the quarter, topping the consensus estimate of $3.00 by $0.43. Becton, Dickinson and Company had a net margin of 8.47% and a return on equity of 15.74%. On average, sell-side analysts anticipate that Becton, Dickinson and Company will post 14.41 earnings per share for the current fiscal year.

Becton, Dickinson and Company announced that its Board of Directors has approved a share repurchase plan on Tuesday, January 28th that permits the company to repurchase 10,000,000 shares. This repurchase authorization permits the medical instruments supplier to buy shares of its stock through open market purchases. Stock repurchase plans are typically an indication that the company’s board of directors believes its stock is undervalued.

Becton, Dickinson and Company Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Monday, March 31st. Shareholders of record on Monday, March 10th will be given a dividend of $1.04 per share. The ex-dividend date of this dividend is Monday, March 10th. This represents a $4.16 annualized dividend and a yield of 1.81%. Becton, Dickinson and Company’s dividend payout ratio (DPR) is presently 69.10%.

Becton, Dickinson and Company Company Profile

Becton, Dickinson and Company develops, manufactures, and sells medical supplies, devices, laboratory equipment, and diagnostic products for healthcare institutions, physicians, life science researchers, clinical laboratories, pharmaceutical industry, and the general public worldwide. The company operates in three segments: BD Medical, BD Life Sciences, and BD Interventional.